The Surgical Oncology Training Program is designed to attract and train physicians with a clinical background in surgery into a two-year fellowship of basic and translational science research. Fellows will be mentored by and conduct bench-science experiments in the laboratory of established cancer research scientists of the UNC Lineberger Comprehensive Cancer Center (LCCC). Each trainee will also have a surgical oncology clinical mentor to direct the trainee's translational research focus. The two-year experience will include coursework in areas such as ethical conduct of science, molecular biology, signal transduction, biostatistics, animal models or immunology to strengthen their individual science foundation. Fellows will be required to present their work at LCCC conferences as well as at regional and national meetings to ensure their ability to clearly communicate their interpretation of experimental data. Trainees will be competitively selected after a minimum of two years of training in any of the surgical subspecialties, and who have demonstrated potential to pursue academic careers in the care of cancer patients. One or two trainees will be selected in alternate years. Over the next 5 years the research fellowship will be integrated with a nascent Clinical Surgical Oncology Fellowship in the division of surgical oncology.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Schools of Arts and Sciences
Chapel Hill
United States
Zip Code
Damrauer, Jeffrey S; Hoadley, Katherine A; Chism, David D et al. (2014) Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A 111:3110-5
Tignanelli, Christopher J; Herrera Loeza, Silvia G; Yeh, Jen Jen (2014) KRAS and PIK3CA mutation frequencies in patient-derived xenograft models of pancreatic and colorectal cancer are reflective of patient tumors and stable across passages. Am Surg 80:873-7
Chism, David D; De Silva, Dinuka; Whang, Young E (2014) Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer. Expert Rev Anticancer Ther 14:1369-78
Kasamon, Yvette L; Brodsky, Robert A; Borowitz, Michael J et al. (2013) Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia. Leuk Lymphoma 54:483-90
Kasamon, Yvette L; Jacene, Heather A; Gocke, Christopher D et al. (2012) Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood 119:4129-32
Kasamon, Yvette L; Jones, Richard J; Gocke, Christopher D et al. (2011) Extended follow-up of autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide (4-HC) purging for indolent or transformed non-Hodgkin lymphomas. Biol Blood Marrow Transplant 17:365-73
Kimple, Randall J; Vaseva, Angelina V; Cox, Adrienne D et al. (2010) Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status. Clin Cancer Res 16:912-23
Kasamon, Y L; Jones, R J; Brodsky, R A et al. (2010) Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma. Ann Oncol 21:1203-10
Bednarski, Brian K; Baldwin Jr, Albert S; Kim, Hong Jin (2009) Addressing reported pro-apoptotic functions of NF-kappaB: targeted inhibition of canonical NF-kappaB enhances the apoptotic effects of doxorubicin. PLoS One 4:e6992
Goicoechea, S M; Bednarski, B; Garcia-Mata, R et al. (2009) Palladin contributes to invasive motility in human breast cancer cells. Oncogene 28:587-98

Showing the most recent 10 out of 21 publications